Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Neurogene (NGNE) Equity Average (2018 - 2025)

Neurogene's Equity Average history spans 6 years, with the latest figure at $265.2 million for Q4 2025.

  • For Q4 2025, Equity Average rose 18.45% year-over-year to $265.2 million; the TTM value through Dec 2025 reached $265.2 million, up 18.45%, while the annual FY2025 figure was $287.6 million, 15.89% up from the prior year.
  • Equity Average reached $265.2 million in Q4 2025 per NGNE's latest filing, down from $269.4 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $301.1 million in Q1 2025 to a low of -$176.1 million in Q3 2023.
  • Average Equity Average over 3 years is $126.1 million, with a median of $170.6 million recorded in 2024.
  • Peak YoY movement for Equity Average: soared 15807.25% in 2024, then increased 18.45% in 2025.
  • A 3-year view of Equity Average shows it stood at $1.4 million in 2023, then skyrocketed by 15807.25% to $223.9 million in 2024, then rose by 18.45% to $265.2 million in 2025.
  • Per Business Quant, the three most recent readings for NGNE's Equity Average are $265.2 million (Q4 2025), $269.4 million (Q3 2025), and $282.5 million (Q2 2025).